AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Psychedelicalpha

Published November 9, 2026

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

Read the full story at Psychedelicalpha

FDA is now reviewing three psychedelic NDAs, following the resubmission of Resilient Pharmaceuticals' MDMA for PTSD applications this summer, and the.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic press release